Amplia Therapeutics Limited (ATX) Fair Value & Analysis
Healthcare · AU · Market cap A$61.6M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 4 days ago
Fair value updated Jun 26, 2026 — revised from A$0.3500 to A$0.3600 (+2.9%) since Jun 24, 2026. Share price +7.4% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.1024 – A$0.3305 · fair‑value band A$0.2200 – A$0.4700 · the A$0.1350 price screens below the A$0.3600 fair value. As of Jun 26, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Amplia Therapeutics Limited (ATX) currently trades at A$0.1350, while our model-based Fair Value estimate is A$0.3600 — implying the stock looks roughly 166.7% undervalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at A$4.8M. Revenue declined 9.1% year over year. It earns a return on equity of -25.5%. The balance sheet holds a net cash position of A$27.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Revenue & earnings trend
FY2021 – FY2026 · reported fiscal years
Amplia Therapeutics Limited reported revenue of A$3.8M in FY2025 versus A$1.5M in FY2021, a compound +25.3%/yr. Reported net income was −A$7.7M in FY2026.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Amplia Therapeutics Limited (ATX) undervalued?
What is the fair value of ATX?
What is the quality score of ATX?
What is the revenue of Amplia Therapeutics Limited (ATX)?
What is the net profit margin of ATX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.